Congenital Adrenal Hyperplasia—More Dogma Bites the Dust
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Congenital adrenal hyperplasia (CAH) has fascinated physicians and sociologists at least since 1865, when de Crecchio published his famous autopsy and social report of a person whose sex of rearing was ambivalent in early childhood and who lived as a man, died in an apparent Addisonian crisis, and was found to have hyperplastic adrenals, a uterus, fallopian tubes, and ovaries at autopsy (described in Ref. 1). The hormonal basis of CAH was elucidated in the 1950s, illustrating the transition of endocrinology from descriptive clinical phenomenology to a biochemically based understanding of physiology and disease (reviewed by Ref. 1). This era employed the available crude tools and analytical chemistry to separate, isolate, and characterize steroids from blood and urine. Until recently, much confusion pervaded the literature on adrenal steroidogenesis and its disorders because only a limited number of circulating steroids could be measured by immunoassays. With the advent of radiolabeled steroids in pure form, isotope-tracing technology provided a glimpse of steroid pathways and metabolic flux (2), but the array of steroid biosynthetic and degradative enzymes was unknown, and the substantial differences in steroidogenesis among different mammals were not appreciated. Cytochrome P450 was described in 1962, and the first activity ascribed to P450 enzymes was steroid 21-hydroxylation (3), but it took another decade before it became clear that there were many distinct P450 enzymes participating in steroidogenesis. The advent of molecular cloning technologies in the 1980s rapidly permitted the identification of the various steroidogenic genes and their encoded enzymes (4). Today, we have a very detailed understanding of the molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders (5), yet the discovery of new diseases and pathways of steroidogenesis constantly forces us to revise our ideas and to scrap some long-standing dogma. Now, with parallel advances in mass spectrometrometric methods for comprehensive steroid analysis (6), we have come full circle, and steroid chemistry has regained center stage. In this issue of the JCEM, Kamrath et al. (7) show how advanced technologies applied to urinary steroid analysis—coupled with a broader understanding of the pathways of androgen synthesis—are revising how we conceptualize the origin of androgen excess in CAH. The methodologies employed in this work and the insight gained from the data provide new analytes (biomarkers) that should improve the diagnosis of CAH and the management of this complex disorder. Steroid 21-hydroxylase deficiency (21OHD), which accounts for approximately 95% of the cases of CAH, is caused by mutations in the CYP21A2 gene encoding the adrenal 21-hydroxylase, P450c21 (5). For most of the past 50 yr, the general understanding of this disorder has been that the defective 21-hydroxylase prevents the fetus from producing cortisol, leading to overproduction of ACTH, which then drives adrenal steroidogenesis. In the presence of the block in 21-hydroxylation, however, 17-hydroxyprogesterone (17OHP) accumulates and is then converted to “adrenal androgens.” Pathways in textbooks traditionally showed 17OHP being the principal (or only) precursor of androstenedione, which was regarded as being an androgen as well as being the principal precursor of testosterone. Consequently, the prevailing assumption has been that, in 21OHD, adrenal-derived androstenedione and testosterone are the proximate precursors to dihydrotestosterone (DHT), the critical androgen for virilization of the external genitalia, and that the last step is mediated by steroid 5α-reductase type 2, as in normal boys. As a result of this model for the mechanism of virilization in 21OHD, there has been tremendous focus on 17OHP; this steroid has long been used to diagnose CAH and to monitor its treatment, despite well-documented shortcomings in this use (8). The main problem with this traditional model is that we have known for over 20 yr that the human 17-hydroxylase/17,20-lyase (P450c17) cannot convert 17OHP to androstenedione (Δ4 pathway) to any appreciable extent (9, 10), and it was not until recently that 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5, AKR1C3) was shown to convert androstenedione to testosterone in the human fetal adrenal (11, 12), although conversion of dehydroepiandrosterone (DHEA) to androst-5-ene-3β,17β-diol (A5diol) and then to testosterone is at least equally likely (5). If 17OHP conversion to androstenedione is poor, then DHEA and A5diol (Δ5 pathway) might be the major 19-carbon steroids produced by the adrenal in 21OHD, which are then metabolized to DHT by peripheral enzymes. The difficulty with this view is that the fetal adrenal normally produces abundant DHEA sulfate, and any androstenedione and testosterone formed after about 20 wk gestation is normally converted to estrogen in the placenta, defending the female fetus from vir
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Self-citationSpeiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468
Self-citationMutant P450 oxidoreductase causes disordered steroidogenesis with and without Antley-Bixler syndrome
Flück, C. E., Tajima, T., Pandey, A. V., Arlt, W., Okuhara, K., Verge, C. F., Jabs, E. W., Mendonça, B. B., Fujieda, K., & Miller, W. L. (2004) · Nature Genetics · doi:10.1038/ng1300 · Cited by 509
Self-citationThe backdoor pathway to dihydrotestosterone
Auchus, R. J. (2004) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2004.09.004 · Cited by 347
Self-citationArlt, W., Walker, E. A., Draper, N., Ivison, H. E., Ride, J. P., Hammer, F., Chalder, S. M., Borucka-Mankiewicz, M., Hauffa, B. P., Malunowicz, E. M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16503-3 · Cited by 345
In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development
Goto, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25091 · Cited by 284
Flück, C. E., Meyer-Böni, M., Pandey, A. V., Kempná, P., Miller, W. L., Schoenle, E. J., & Biason-Lauber, A. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.06.009 · Cited by 248
Self-citationKamrath, C., Hochberg, Z., Hartmann, M. F., Remer, T., & Wudy, S. A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1997 · Cited by 191
Wilson, J. D., Auchus, R. J., Leihy, M. W., Guryev, O. L., Estabrook, R. W., Osborn, S. M., Shaw, G., & Renfree, M. B. (2003) · Endocrinology · doi:10.1210/en.2002-220721 · Cited by 172
Self-citationHomma, K., Hasegawa, T., Nagai, T., Adachi, M., Horikawa, R., Fujiwara, I., Tajima, T., Takeda, R., Fukami, M., & Ogata, T. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2460 · Cited by 153
Nakamura, Y., Hornsby, P. J., Casson, P., Morimoto, R., Satoh, F., Xing, Y., Kennedy, M. R., Sasano, H., & Rainey, W. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2374 · Cited by 129
Shackleton, C., Marcos, J., Arlt, W., & Hauffa, B. P. (2004) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30171 · Cited by 104
5α-Reduced C21 steroids are substrates for human cytochrome P450c17
Gupta, M. K., Guryev, O. L., & Auchus, R. J. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2003.07.003 · Cited by 84
Self-citation
Cited by
Alternative (backdoor) androgen production and masculinization in the human fetus
O’Shaughnessy, P. J., Antignac, J. P., Le Bizec, B., Morvan, M.-L., Svechnikov, K., Söder, O., Savchuk, I., Monteiro, A., Soffientini, U., Johnston, Z. C., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000002 · Cited by 177
Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer
Ferraldeschi, R., Sharifi, N., Auchus, R. J., & Attard, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0931 · Cited by 93
Self-citationPsychoendocrinology of Congenital Adrenal Hyperplasia
Meyer-Bahlburg, H. F. L. (2014) · Genetic Steroid Disorders · doi:10.1016/b978-0-12-416006-4.00023-5 · Cited by 48
Fetal endocrine therapy for congenital adrenal hyperplasia should not be done
Miller, W. L. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.01.005 · Cited by 40
Self-citationKaupert, L., Lemos‐Marini, S., De Mello, M., Moreira, R., Brito, V., Jorge, A., Longui, C., Guerra, G., Mendonca, B., & Bachega, T. (2013) · Clinical Genetics · doi:10.1111/cge.12016 · Cited by 17
Metadata
- Authors
- Auchus, R. J., & Miller, W. L.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-03-01
- Volume
- 97
- Issue
- 3
- Pages
- 772-775
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2042831623
- Cited by
- 22
- References
- 13
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.